European public procurement and grants data from official registers · Data as of 19 November 2026; updated daily.

Tenders

Dermatological drug tenders in Czechia

Dermatological drug tenders in Czechia: 147 listed on GranTender since 2024. The median awarded contract value is about €580,000 (242 contracts with a stated value). Buyers with the most tenders: Fakultní nemocnice Olomouc (28), Fakultní nemocnice Ostrava (13) and Krajská zdravotní, a.s. (10); suppliers with the most contract awards: Amgen s.r.o. (28), ROCHE s.r.o. (18) and Takeda Pharmaceuticals Czech Republic s.r.o. (10). Sources: Registr smluv, ISVZ (NIPEZ) and TED. In 2025 the median contract value was €390,000; 58% of contracts drew a single bid (1.6 bids on average). Data as of 19 November 2026; updated daily.

Tenders
147
Open tenders
0
Awards
378
Awarded value awarded
€524,188,637
Awarded value contract
€63,539,041
Awarded value framework ceiling
€105,758,144
Median contract value awarded
≈ €580,000
Median contract value contract
≈ €100,000
Median contract value framework ceiling
≈ €73,000
Average bids per contract
1.5
Tenders in 2025
67 +76% on 2024

Median: contracts with a stated value, rounded. Average bids: contracts where the number of bids is published.

Value kinds: awarded — the value in the award decision; contract — the value of the signed or amended contract; paid — the amount actually paid; framework ceiling — the maximum of a framework agreement, given with every winner, not money spent. Different kinds are never added together.

Open tenders

No records yet.

Latest tenders

TenderBuyerEstimated valueStatusPublished
Léčivé přípravky s obsahem alopurinoluFakultní nemocnice Hradec KrálovéCZK 819,900 (≈ €33,746)Closed23 September 2026
Léčivé přípravky s obsahem alopurinoluFakultní nemocnice Hradec KrálovéCZK 819,900 (≈ €33,746)Closed23 September 2026
Dodávky LP - společný nákupFakultní nemocnice BulovkaCZK 2,509,611,143 (≈ €103,293,182)Closed21 September 2026
Léčivé přípravky s obsahem botulotoxinuFakultní nemocnice Hradec KrálovéCZK 13,584,731 (≈ €559,134)Closed10 August 2026
Léčivé přípravky s obsahem botulotoxinuFakultní nemocnice Hradec KrálovéCZK 13,578,030 (≈ €558,859)Closed10 August 2026
Výzva č. 291 - Nusinersen – Dynamický nákupní systém na dodávky léčivých přípravkůFakultní nemocnice Motol a Homolka—Awarded7 August 2026
Léčivé přípravky s obsahem romosozumabuFakultní nemocnice Hradec KrálovéCZK 6,184,000 (≈ €254,527)Awarded3 August 2026
Léčivé přípravky s obsahem romosozumabuFakultní nemocnice Hradec KrálovéCZK 6,184,000 (≈ €254,527)Awarded3 August 2026
Léčivé přípravky s obsahem romosozumabuFakultní nemocnice Hradec Králové—Awarded31 July 2026
DYNAMICKÝ NÁKUPNÍ SYSTÉM PRO PRŮBĚŽNÉ A OPAKOVANÉ NÁKUPY LÉČIVÝCH PŘÍPRAVKŮ_Červenec_27/2026 - HEMIHYDRÁT UPADACITINIBUVšeobecná fakultní nemocnice v Praze—Awarded29 July 2026
DNS – Kyselina hyaluronováÚstřední vojenská nemocnice - Vojenská fakultní nemocnice PrahaCZK 1,541,792 (≈ €63,459)Closed2 July 2026
Výzva č. 278 Burosumab – Dynamický nákupní systém na dodávky léčivých přípravkůFakultní nemocnice Motol a Homolka—Awarded4 June 2026
Přístroj na míchání mastí IVFakultní nemocnice Olomouc—Cancelled1 June 2026
DYNAMICKÝ NÁKUPNÍ SYSTÉM PRO PRŮBĚŽNÉ A OPAKOVANÉ NÁKUPY LÉČIVÝCH PŘÍPRAVKŮ_Duben_9/2026 – BIMEKIZUMAB opakovanáVšeobecná fakultní nemocnice v Praze—Awarded27 April 2026
Přístroj na míchání mastí IIIFakultní nemocnice Olomouc—Cancelled14 April 2026
VN Brno - Lebrikizumab 2026 IIIVojenská nemocnice Brno—Awarded27 March 2026
Léčivé přípravky s obsahem cisatrakuriaFakultní nemocnice Hradec KrálovéCZK 2,453,610 (≈ €100,988)Awarded24 March 2026
Léčivé přípravky s obsahem cisatrakuriaFakultní nemocnice Hradec KrálovéCZK 2,453,610 (≈ €100,988)Awarded24 March 2026
Léčivé přípravky s obsahem cisatrakuriaFakultní nemocnice Hradec Králové—Awarded23 March 2026
VN Brno - Lebrikizumab 2026 IIVojenská nemocnice Brno—Cancelled17 March 2026

Competition and prices

In 2025, half of the contracts were worth between €97,000 and €1.6 million, with a median of €390,000 (90 contracts with a stated awarded value). Contracts drew 1.6 bids on average (median 1) and 58% drew a single bid — based on 144 contracts with a known number of bids. Compared with 2024, in 2025 the median value fell 9% and the share of single-bid contracts fell from 86% to 58%. The usual procedures: open procedure (72%), other procedures (24%), negotiation without a call for competition (1%) — of 136 tenders with a stated procedure.

The most contracts went to Amgen s.r.o. (28), ROCHE s.r.o. (18) and Takeda Pharmaceuticals Czech Republic s.r.o. (10) — together 15% of all contracts.

YearContractsMedian valueMiddle half of valuesBids on averageSingle bid
202457€430,000€37,000 – €1.2 million1.386% (35)
2025149€390,000€97,000 – €1.6 million1.658% (144)
2026 (so far)160€870,000€340,000 – €2.1 million1.573% (156)
All years370€610,000€170,000 – €1.9 million1.568% (335)

Values: contracts with a stated value in EUR, each value kind on its own (awarded or contract value), approximate (±3 %). Bids: contracts of procedures with competition whose number of bids the source publishes (1–100 bids); the sources publish it for some contracts only (TED ≈ 3 in 4, Spain all, Poland about half, Italy few), so each figure states its base and is shown from 20 contracts. A contract counts in the year of its award (else of its tender). Figures as of 13 November 2026, recomputed every week.

Where you have a chance

Since 1 November 2024, 66% of the 315 contracts with a known number of bids had a single bid; the median was 1 bid. The number of bids is known for 315 of the 322 contracts from procedures with competition.

Buyers who often get few offers

The buyers below usually received one or two offers per contract — an offer from you would stand out.

In the last 12 months, 0 companies won their first contract in our records here — 0% of the 60 contracts (our records start on 1 January 2024).

Contracts awarded since 1 November 2024 (the last 24 months). Bids as the source publishes them, 1 to 100 per contract, in procedures with competition only (a direct award has one offer by design). As of 13 November 2026.

Main CPV divisions

CPV codes of this topic

  • 33630000 Medicinal products for dermatology and the musculo-skeletal system

A tender belongs here when its main CPV code starts with one of these codes; a tender without a usable CPV code (or with a general one) is matched by words of its title. A tender may belong to up to three topics.

Dermatological and musculoskeletal drugs in neighbouring countries

Today, 5 tenders in the same niche are open in neighbouring countries.

Public tenders in the EU and the EEA are open to companies from every EU and EEA country on the same terms as local ones, and to companies from countries with a procurement agreement with the EU (such as Switzerland, the United Kingdom and Ukraine) for the contracts it covers. Open means the deadline has not passed (today's date). Neighbours: countries with a land border, a fixed link or a short sea crossing.

Expected soon1

ExpectedBuyerWhatWhy we expect itConfidence
Dec 2026 – May 2027
contract ends
Nemocnice Znojmo, příspěvková organizaceDermatological and musculoskeletal drugs
Dodávky léčivých přípravků s účinnou látkou Dupilumabum
Typical value: ≈ €100,000
The current contract with Boehringer Ingelheim, spol. s r.o. ends on 2 June 2027; no new tender has been published yet.
Earlier tenders: 08/2024
medium

Forecast from public data, not an announcement. Methodology.

Market reports

Dermatological and musculoskeletal drugs by city

Dermatological and musculoskeletal drugs in other countries

Dermatological and musculoskeletal drugs across Europe

Topics in Health, medical equipment and medicines

Questions and answers

Where can I find dermatological drug tenders in Czechia?
GranTender lists them in one place, from Registr smluv, ISVZ (NIPEZ) and TED, with their buyers, winners and contract values. Search in one country at a time (the first 5 results) is free; search across all countries at once, full result lists, saved keywords with an e-mail once a week and exports come with a plan.
Who wins the most dermatological drug tenders in Czechia?
By number of contracts won: Amgen s.r.o. (28), ROCHE s.r.o. (18), Takeda Pharmaceuticals Czech Republic s.r.o. (10).
Which buyers publish the most dermatological drug tenders in Czechia?
By number of tenders: Fakultní nemocnice Olomouc (28), Fakultní nemocnice Ostrava (13), Krajská zdravotní, a.s. (10).
Which CPV codes belong to “Dermatological and musculoskeletal drugs”?
33630000 Medicinal products for dermatology and the musculo-skeletal system; plus tenders without a usable CPV code whose title names the topic.
How many bids do dermatological drug tenders in Czechia receive on average?
In 2025, contracts drew 1.6 bids on average (median 1) and 58% drew a single bid — based on 144 contracts with a known number of bids.
How much are contracts for dermatological drug tenders in Czechia worth?
In 2025, half of the contracts were worth between €97,000 and €1.6 million, with a median of €390,000 (90 contracts with a stated awarded value). Compared with 2024, in 2025 the median value fell 9% and the share of single-bid contracts fell from 86% to 58%.
Which procedures are used for dermatological drug tenders in Czechia?
The usual procedures: open procedure (72%), other procedures (24%), negotiation without a call for competition (1%) — of 136 tenders with a stated procedure.
Which buyers get few offers in dermatological drug tenders in Czechia?
Since 1 November 2024, these buyers usually received one or two offers per contract: Fakultní nemocnice Olomouc (median 2 bids over 34 contracts), Nemocnice Znojmo, příspěvková organizace (median 1 bid over 29 contracts) and Fakultní nemocnice Ostrava (median 1 bid over 10 contracts). Since 1 November 2024, 66% of the 315 contracts with a known number of bids had a single bid; the median was 1 bid.

CPV 2008 (Regulation (EC) No 213/2008), © European Union, Publications Office — via the eForms SDK, CC BY 4.0.